4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers
AssigneeAmerican Home Products Corporation
InventorsJohn Anthony Butera, Joseph Richard Lennox, Douglas John Jenkins
Life of this patent
Estimating the term…
Abstract
4-Substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones having the Formula (I): 1 wherein R1, R2, R3, R4, R5, A and W are as defined in the specification which compounds relaxes smooth muscles.
Claims59
A compound having the Formula (I):
- 32
- wherein:
- R1, R2, and R3, are, independently, hydrogen, halogen, nitro, cyano, alkyl of 1 to 10 carbon atoms (optionally substituted with halogen), cycloalkyl of 3 to 10 carbon atoms, —OR7, amino, alkylamino of 1 to 10 carbon atoms, —SO3H, —SO2NH2, —SONH2, —NHSO2R7,
- 33
- —SO2R7, carboxyl, aryl of 6 to 12 carbon atoms or aroyl of 7 to 12 carbon atoms;
- A is a moiety selected from the group consisting of a bond, —CH2—, —CH═CH— and —CHCOR6;
- W is selected from the group consisting of carbon and nitrogen and wherein the carbon atom may be optionally substituted with -R1, -R2 and -R3;
- R4 is a alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, aralkyl of 7 to 20 carbon atoms, wherein the aryl group is optionally substituted with alkyl of 1 to 10 carbon atoms, nitro, halogen cyano, —OR7,
- 34
- trifluoromethyl or trifluoromethoxy;
- R5 is hydrogen, alkyl of 1 to 10 carbon atoms, formyl, alkanoyl of 2 to 7 carbon atoms, alkenoyl of 3 to 7 carbon atoms,
- 35
- —SO2R7, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms;
- R6 is alkyl of 1 to 10 carbon atoms, or aryl of 6 to 12 carbon atoms;
- R7 is a alkyl of 1 to 10 carbon atoms (optionally substituted with halogen);
- aroyl is benzoyl and naphthoyl optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, —CF3, and phenyl;
- aryl is naphthyl, phenyl or phenyl optionally substituted with one to three substituents each independently selected from the group halogen, carboxy, alkyl of 1 to 10 carbon atoms, nitro, amino, alkoxy of 1 to 10 carbon atoms, and alkylamino of 1 to 10 carbon atoms;
- with the following provisos that A is not a bond and W is not a carbon bearing a hydrogen;
- a) when R1 and R2 are H;
- R3 is selected from the group consisting of H, 4-methyl, 4-chloro, 4-nitro and 4-methoxy;
- and R4 and R5 are simultaneously methyl or ethyl;
- b) when R1, R2, R3 and R5 are H;
- and R4 is butyl;
- c) when R1, R2 and R5 are H;
- R3 is 4-halo and R4 is alkyl of 1 to 4 carbon atoms;
- d) when R1 is selected from the group consisting of H, 2-methyl, 2-ethyl and 2-methoxy;
- R2 and R5 are H;
- R3 is 4-dimethylamino and R4 is 2-propyl;
- or pharmaceutically acceptable salts thereof.
A pharmaceutical composition for treating or inhibiting disorders associated with smooth muscle contraction, via potassium channel modulation in warm-blooded animals in need thereof, which comprises administering to said warm-blooded animals, an effective amount of a compound of general Formula (II)
- 38
- wherein:
- R1, R2, and R3, are, independently, hydrogen, halogen, nitro, cyano, alkyl of 1 to 10 carbon atoms (optionally substituted with halogen), cycloalkyl of 3 to 10 carbon atoms, —OR7, amino, alkylamino of 1 to 10 carbon atoms, —SO3H, —SO2N2, —SONH2, —NHSO2R7,
- 39
- —SO2R7, carboxyl, aryl of 6 to 12 carbon atoms or aroyl of 7 to 12 carbon atoms;
- A is a moiety selected from the group consisting of a bond, —CH2—, —CH═CH— and —CHCOR6;
- W is selected from the group consisting of carbon and nitrogen and wherein the carbon atom may be optionally substituted with -R1, -R2 and -R3;
- R4 is alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, aralkyl of 7 to 20 carbon atoms wherein the aryl group is optionally substituted with alkyl of 1 to 10 carbon atoms cyano, —OR7,
- 40
- trifluoromethyl or trifluoromethoxy;
- R5 is hydrogen, alkyl of 1 to 10 carbon atoms, formyl, alkanoyl of 2 to 7 carbon atoms, alkenoyl of 3 to 7 carbon atoms,
- 41
- —SO2R7, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkenoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms;
- R6 is a chain alkyl of 1 to 10 carbon atoms, or aryl of 6 to 12 carbon atoms;
- R7 is alkyl of 1 to 10 carbon atoms (optionally substituted with halogen);
- aroyl is benzoyl and naphthoyl optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 Carbon atoms,
- —CF3, and phenyl;
- aryl is naphthyl, phenyl or phenyl optionally substituted with one to three substituents each independently selected from the group halogen, carboxy, alkyl of 1 to 10 carbon atoms, nitro, amino, alkoxy of 1 to 10 carbon atoms, and alkylamino of 1 to 10 carbon atoms;
- or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers or excipients.
A method of treating or inhibiting disorders associated with smooth muscle contraction, via potassium channel modulation in warm-blooded animals in need thereof, which comprises administering to said warm-blooded animals, an effective amount of a compound of general Formula (II);
- 44
- wherein:
- R1, R2, and R3, are, independently, hydrogen, halogen, nitro, cyano, alkyl of 1 to 10 carbon atoms (optionally substituted with halogen) cycloalkyl of 3 to 10 carbon atoms, —OR7, amino, alkylamino of 1 to 10 carbon atoms, —SO3H, —SO2NH2, —SONH2, —NHSO2R7,
- 45
- —SO2R7, carboxyl, aryl of 6 to 12 carbon atoms or aroyl of 7 to 12 carbon atoms;
- A is a moiety selected from the group consisting of a bond, —CH2—, —CH═CH— and —CHCOR6;
- W is selected from the group consisting of carbon and nitrogen and wherein the carbon atom may be optionally substituted with -R1,-R2and -R3;
- R4 is alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, aralkyl of 7 to 20 carbon atoms, wherein the aryl group is optionally substituted with alkyl of 1 to 10 carbon atoms, nitro, halogen, cyano, —OR7,
- 46
- trifluoromethyl or trifluoromethoxy;
- R5 is hydrogen, alkyl of 1 to 10 carbon atoms, formyl, alkanoyl of 2 to 7 carbon atoms, alkenoyl of 3 to 7 carbon atoms,
- 47
- —SO2R7, aroyl of 7 to 12 carbon atoms, arylalkenoyl of 9 to 20 carbon atoms, arylsulfonyl of 6 to 12 carbon atoms, arylalkanoyl of 8 to 12 carbon atoms or arylalkylsulfonyl of 7 to 12 carbon atoms;
- R6 is alkyl of 1 to 10 carbon atoms, or aryl of 6 to 12 carbon atoms;
- R7 is alkyl of 1 to 10 carbon atoms (optionally substituted with halogen);
- aroyl is benzoyl and naphthoyl optionally substituted with one to three substituents each independently selected from the group halogen, cyano, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, —CF3, and phenyl;
- aryl is naphthyl, phenyl or phenyl optionally substituted with one to three substituents each independently selected from the group halogen, carboxy, alkyl of 1 to 10 carbon atoms, nitro, amino, alkoxy of 1 to 10 carbon atoms, and alkylamino of 1 to 10 carbon atoms;
- or a pharmaceutically acceptable salt.
Dependencies are inferred from the claim text.